Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.

Abstract: The present disclosure relates to novel CDK inhibitors, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions associated with CDK.

Abstract: The present application discloses a method and an apparatus for a media stream transmission based on an edge device, and an electronic device. The method includes: an edge all-in-one machine located in a second network receives a live streaming request message from a station device management cloud module in a first network, generates media stream service information based on an identifier of a camera module, and sends the media stream service information to the station device management cloud module to cause the station device management cloud module to request a media stream from a target network video recorder. The edge all-in-one machine further receives the media stream recorded by the target network video recorder through the camera module, and transmits the media stream to a client based on the edge live streaming address.

Abstract: The present disclosure provides a device driving method, apparatus, and electronic device. The method comprises: receiving call parameters comprising a device identification, a device class, and a driving instruction of a target device; looking up a target function-class module matching the device class in at least one function-class module according to the device class and a pre-set first mapping relationship; looking up, by using the target function-class module, a target function sub-module in at least one function sub-module according to the device identification and a second mapping relationship; sending the driving instruction to the target device via the target function sub-module, to drive the target device to execute a task corresponding to the driving instruction.

Abstract: The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

Abstract: Embodiments of the disclosure discloses a service management system, a service management method, a device and a storage medium. The system includes a server, a plurality of devices, and a plurality of clients establishing a communication connection with the plurality of devices; the server is configured to receive a service execution request, determine a target client from the plurality of clients based on an identifier of a target client comprised in the service execution request, and forward the service execution request to the target client; and the target client is configured to parse service information comprised in the service execution request, determine a target device corresponding to the service information from the plurality of devices, generate a driving instruction for the target device by invoking a target device driving service of the target device, and drive the target device with the driving instruction to respond to the service information.

Abstract: The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2? breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.

Abstract: The application relates to a run-length stripping method for generating skeleton lines of complex plain river networks, including following steps: 1. constructing an empty raster field, each raster row generates an empty run-length linked list; 2. completing raster compression on each row, and compressing the continuous grids into run-length units and inserting them into the raster row run-length linked list; 3. establishing a raster field river boundary grid search template; 4. setting two discriminant functions to judge whether a grid on a raster field is a redundant grid; 5. searching all boundary grids along a raster field boundary, and marking and stripping all redundant grids based on two discriminant functions respectively; 6. analyzing whether the boundary grid is stripped, if so, returning to continue stripping, otherwise, entering the next step; 7. converting the non-stripped grid into skeleton line data in vector form.

Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.

Abstract: The present disclosure relates to at least one entity chosen from a compound of Formula (I), tautomers, stereoisomers or a mixture of stereoisomers, hydrates, and deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, and their use as epidermal growth factor receptor (EGFR) degraders for the prevention and treatment of diseases and conditions, e.g., cancer. The present disclosure also relates to pharmaceutical compositions containing such entities, and their use in treating or preventing a disease or disorder associated with EGFR.

Abstract: Spirocyclic compounds that are KLHDC2 ligands and methods for inhibiting the enzymatic activity of KLHDC2 using the ligands.

Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Abstract: The present disclosure relates to novel glutarimide-containing compounds with KRAS mutant form degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions.

Abstract: The disclosure provides quinazoline based compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.

Abstract: The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) TBK1. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds TBK1 such that TBK1 is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of TBK1. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of TBK1.

Abstract: The application relates to a run-length stripping method for generating skeleton lines of complex plain river networks, including following steps: 1. constructing an empty raster field, each raster row generates an empty run-length linked list; 2. completing raster compression on each row, and compressing the continuous grids into run-length units and inserting them into the raster row run-length linked list; 3. establishing a raster field river boundary grid search template; 4. setting two discriminant functions to judge whether a grid on a raster field is a redundant grid; 5. searching all boundary grids along a raster field boundary, and marking and stripping all redundant grids based on two discriminant functions respectively; 6. analyzing whether the boundary grid is stripped, if so, returning to continue stripping, otherwise, entering the next step; 7. converting the non-stripped grid into skeleton line data in vector form.

Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.

Abstract: The present disclosure relates to a compound of Formula (I), a tautomer, a stereoisomer or a mixture of stereoisomers, a pharmaceutically acceptable salt, a hydrate, or a deuterated derivative thereof and their use in, e.g., treating a disease or disorder associated with CDK2. The present disclosure also relates to pharmaceutical compositions containing such compounds, and their use in treating or preventing a disease or disorder associated with CDK2.